Scholar Rock Holding Corporation $SRRK Stock Holdings Increased by EFG Asset Management North America Corp.

EFG Asset Management North America Corp. raised its position in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) by 71.2% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 88,106 shares of the company’s stock after purchasing an additional 36,628 shares during the quarter. EFG Asset Management North America Corp.’s holdings in Scholar Rock were worth $3,279,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in SRRK. Bellevue Group AG raised its position in shares of Scholar Rock by 17.6% during the 2nd quarter. Bellevue Group AG now owns 2,947,295 shares of the company’s stock valued at $104,393,000 after acquiring an additional 440,405 shares in the last quarter. Eventide Asset Management LLC increased its stake in Scholar Rock by 9.5% during the second quarter. Eventide Asset Management LLC now owns 2,913,246 shares of the company’s stock valued at $103,192,000 after purchasing an additional 251,638 shares during the last quarter. Hood River Capital Management LLC lifted its position in shares of Scholar Rock by 1.6% in the 2nd quarter. Hood River Capital Management LLC now owns 1,974,964 shares of the company’s stock worth $69,953,000 after buying an additional 30,806 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Scholar Rock by 2.2% in the 2nd quarter. Geode Capital Management LLC now owns 1,887,410 shares of the company’s stock valued at $66,861,000 after buying an additional 39,961 shares during the period. Finally, Marshall Wace LLP boosted its holdings in shares of Scholar Rock by 0.3% in the 2nd quarter. Marshall Wace LLP now owns 1,640,437 shares of the company’s stock valued at $58,104,000 after buying an additional 5,137 shares during the period. Institutional investors and hedge funds own 91.08% of the company’s stock.

Insider Activity

In other Scholar Rock news, CEO David Hallal sold 57,450 shares of the business’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $42.70, for a total transaction of $2,453,115.00. Following the sale, the chief executive officer directly owned 1,541,645 shares in the company, valued at approximately $65,828,241.50. The trade was a 3.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Vikas Sinha sold 16,755 shares of the stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $42.70, for a total transaction of $715,438.50. Following the completion of the transaction, the chief financial officer owned 583,245 shares of the company’s stock, valued at $24,904,561.50. This trade represents a 2.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 305,687 shares of company stock worth $13,540,573 in the last 90 days. 13.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on SRRK shares. Citigroup started coverage on shares of Scholar Rock in a report on Friday, January 9th. They issued a “buy” rating and a $55.00 target price on the stock. Bank of America began coverage on Scholar Rock in a research report on Thursday, October 9th. They set a “buy” rating and a $53.00 price objective for the company. JPMorgan Chase & Co. increased their target price on Scholar Rock from $46.00 to $47.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. BMO Capital Markets reissued an “outperform” rating and set a $50.00 price target on shares of Scholar Rock in a report on Friday, November 14th. Finally, HC Wainwright increased their price objective on shares of Scholar Rock from $44.00 to $58.00 and gave the stock a “buy” rating in a report on Monday. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $51.14.

Scholar Rock Trading Up 1.4%

Shares of SRRK stock opened at $44.89 on Tuesday. Scholar Rock Holding Corporation has a 1 year low of $22.71 and a 1 year high of $48.28. The firm has a market capitalization of $4.58 billion, a PE ratio of -14.25 and a beta of 0.63. The stock has a fifty day moving average of $43.89 and a two-hundred day moving average of $37.37. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same quarter last year, the company posted ($0.66) EPS. As a group, research analysts expect that Scholar Rock Holding Corporation will post -2.42 EPS for the current year.

Scholar Rock Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).